Navigation Links
New diagnostic test for bladder cancer

Copenhagen, Denmark Researchers from the Danish Cancer Society and the Herlev University Hospital of Copenhagen have developed a novel assay to test for multiple tumor markers in bladder cancer. The related report by Serizawa et al, "Custom-designed MLPA using multiple short synthetic probes: application to methylation analysis of five promoter CpG islands in tumor and urine specimens from patients with bladder cancer," appears in the July 2010 issue of The Journal of Molecular Diagnostics.

Bladder cancer is the fourth most common type of cancer in men in the United States. Over 50,000 men are diagnosed with bladder cancer each year. Although early-stage superficial tumors can be shaved off or treated with BCG immunotherapy, late-stage patients with infiltrating tumor often require a cystectomy (removal of all or part of the bladder). Therefore, early diagnosis of bladder cancer is critical in maintaining lifestyle standards.

Methylation specific-multiplex ligation-dependent probe amplication (MS-MLPA) can be used to screen multiple target sequences simultaneously in a single reaction, allowing for rapid early screening of tumor markers. However, commercially available MS-MLPA kits are not available for many diseases, and custom probe design has been limited by problems of chemically synthesizing longer nucleotides. Researchers led by Dr. Per Guldberg of the Danish Cancer Society have now modified this assay by using multiple short synthetic probes to test for tumor markers in bladder cancer. They found that paired tumor and urine samples in most cases showed identical marker patterns, suggesting that this assay may be used for non-invasive diagnosis and disease monitoring.

Serizawa et al suggest that "the use of multiple short synthetic probes may provide a simple and cost-effective approach to custom-designed MLPA." In future studies, Dr. Guldberg's group will examine how "the same approach may be used for most other MLPA applications and thus provide the basis for a more widespread usage of the MLPA technology."


Contact: Angela Colmone, Ph.D.
American Journal of Pathology

Related biology news :

1. New chemically-sensitive MRI scan may bypass some invasive diagnostic tests in next decade
2. U of MN researchers discover noninvasive diagnostic tool for brain diseases
3. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
4. Smiths Detection to launch a portable diagnostic system for foot-and-mouth disease and avian flu
5. Arbor Vita rapid H5N1 flu diagnostic presented at ICEID meeting
6. First diagnostic test for Alzheimers and Parkinsons disease on the horizon
7. Fluorescent nano-barcodes could revolutionize diagnostics
8. New electrostatic-based DNA microarray technique could revolutionize medical diagnostics
9. AACR hosts Molecular Diagnostics in Cancer Therapeutic Development Meeting
10. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
11. European researchers harness unique properties of boron to develop new drugs and diagnostics
Post Your Comments:
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
(Date:11/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), the leading ... into the automotive market with a comprehensive and dedicated ... consumer electronics human interface innovation. Synaptics, industry-leading touch controllers, ... automotive industry and will be implemented in numerous locations ... , Japan , and ...
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... Tech Association (MHTA) as one of only three finalists ... "Software – Small and Growing" category. The Tekne Awards honor ... have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... featured on AngelList early in their initial angel funding process. Now, they are ... individuals looking to make early stage investments in the microbiome space. In ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
Breaking Biology Technology: